WindRose Health Investors Makes Majority Growth Investment in SubjectWell

WindRose Health Investors Merges Clariness and SubjectWell to Create Global Patient Recruitment Platform

January 29, 2026

Healthcare Services

WindRose Health Investors led a transaction merging Clariness and SubjectWell into a single global patient recruitment platform that will operate under the Clariness name. The combined company brings broader geographic reach, technology and a large patient database to support clinical trials across 60+ countries and accelerate enrollment and retention for sponsors, CROs and sites.

WindRose Health Investors Makes Growth Investment in Workplace Options

November 1, 2021

Healthcare Services

WindRose Health Investors has made an equity investment in Workplace Options to accelerate the wellbeing provider's growth, innovation, and global expansion. Workplace Options' management will remain in place and continue as active shareholders while the investment supports expanded market share and product capabilities.

WindRose Health Investors Invests in Stellus Rx

December 8, 2025

Healthcare Services

WindRose Health Investors has made a strategic growth investment in Stellus Rx, a Plano, Texas–based technology-enabled, value-based pharmacy care management platform. The undisclosed transaction will fund Stellus Rx’s expansion of clinical and operational capabilities and the scaling of its platform to serve additional patient populations nationwide.

WindRose Health Investors Recapitalizes Veristat Group Inc.

April 7, 2021

Healthcare Services

WindRose Health Investors completed an equity recapitalization of Veristat Group Inc., a global clinical research organization, with Veristat management retaining a significant minority stake. The investment will provide capital and strategic resources to support Veristat's growth and expansion across clinical development, regulatory affairs, biostatistics, data management and pharmacovigilance; terms were not disclosed.

WindRose Health Investors Recapitalizes Lykan Bioscience Holdings

June 4, 2019

Biotechnology

WindRose Health Investors completed an equity recapitalization of Lykan Bioscience Holdings, LLC, a Hopkinton, Massachusetts-based contract manufacturing services organization focused on cell and gene therapy production and logistics. The investment provides capital to support growth and the build-out of a 60,000+ square foot cGMP facility to expand manufacturing capacity; terms were not disclosed.

WindRose Health Investors Recapitalizes Healthmap Solutions

May 21, 2019

Healthcare Services

WindRose Health Investors completed an $85 million equity recapitalization of Healthmap Solutions to provide growth capital and support the company's expansion into new markets. Healthmap, a specialty population health management firm focused on kidney disease, will continue to be led by CEO Joe Vattamattam and COO & Founder Andrew Wall.